Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so-familiar routine of meetings, deadlines, and the like has, predictably, returned. To cope, we are quaffing several needed cups of stimulation. Our choice so far today is the flavorful vanilla cinnamon nut. As always, please feel free to join us and, remember, no prescription is required. So there is no need to bother with co-pays or wondering about rebates. Meanwhile, here are some tidbits. Hope your day is smashing and do stay in touch …

The pharmaceutical industry, pilloried by President Trump for the last two years, is war-gaming for the possibility that its worst fear is realized: that Democrats, if they flip control of the House, find common ground with the president to rein in drug prices, The New York Times writes. Democrats say they are determined to squeeze industry prices and profits, and they have a stack of legislative proposals to do so, while drug makers are quietly making contingency plans.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy